Uncomplicated Malaria
Conditions
Brief summary
Artemisinin combination therapies (ACT) are currently recommended for malaria treatment. Artemether-lumefantrine(A-L) and Artesunate+amodiaquine (A+A) have been the most commonly adopted of the recommended ACT regimens. In Ghana, A+A is the current first-line antimalarial treatment in Ghana, but there has been 1 efficacy report of this regimen in Ghana till date. Moreover, the safety of repeated treatments with ACT has been little studied. This study aims to evaluate the efficacy of A+A vs. A-L, as well as the safety of repeated treatments of these regimens in a longitudinal trial in which recruited children will be followed up for 1 year.
Interventions
DRUGamodiaquine+artesunate/artemether-lumefantrine
Sponsors
University of Copenhagen
University of Ghana Medical School
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE
Eligibility
Sex/Gender
ALL
Age
6 Months to 14 Years
Inclusion criteria
* microscopically confirmed acute uncomplicated falciparum malaria; * temperature at screening 37.50C or more or history of fever 24 preceding enrollment; * willingness to comply with follow up schedule; * written informed consent by accompanying parent or guardian
Exclusion criteria
* features of severe malaria or danger signs of malaria * known intolerance or allergy to any of the study medications * known treatment with any of the study medications in the month preceding enrollment * serious underlying disease that may mask outcome assessment
Countries
Ghana
Outcome results
None listed